Accueil > Publications > Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma: the PRODIGE 41-BEVANEC randomised phase II study
Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients wit...